REFERENCES
- Ray MC, Gately LE. Dermatology manifestations of HIV infection in AIDS. Infect Dis Clin North Am 1994; 94: 583–605.
- Agut J, Palacin C, Sacristán A, Ortiz JA. Inhibition of ergosterol synthesis by sertaconazole in Can dida albicans. Arzn Forsch 1992; 42: 718–720.
- Carrillo-Muñoz AJ, Tur-Tur C. Comparative study of antifungal activity of sertaconazole, terbinafine and bifonazole against clinical isolates of Candida spp., Cryptococcus neo-formans and dermatophytes. Chemotherapy 1997; 43: 387-392.
- Drohuet E, Dupont B. In vitro antifungal activity of ser-taconazole. Arzn Forsch 1992; 42: 705–710.
- Palacín C, Tarragó C, Sacristán A, Ortiz JA. Antifungal Activity of sertaconazole in the cutaneos retention time test. J Mycol Med 1995; 5: 35–39.
- Palacín C, Tarragó C, Agut J, Guglietta A. In vitro activity of sertaconazole, fluconazole, ketoconazole, fenticona-zole, clotrimazole and itraconazole against pathogenic vaginal yeast isolates. Methods Find Exp Clin Pharmacol 2001; 23: 61–64.
- Prats G, Mirelis B, Palacin B, et al. Actividad antibacte-riana in vitro de sertaconazol. Rev Esp Quimioter 1995; 8: 325–326.
- Torres J, Márquez M, Camps F. Sertaconazole in the treatment of mycoses: from dermatology to gynecology. Int J Gynaecol Obstet. 2000; 71; Suppl 1: S3–20.
- National Committee for Clinical Laboratory Standards. Reference method for broth dilution antifungal susceptibility testing of filamentous fungi: approved standard. NCCLS docu-ment M38-A. National Committee for Laboratory Standards, Wayne, Pa, 2002.
- Fernández-Torres B, Cabaties FJ, Abarca L, et al. Collaborative evaluation of optimal antifungal susceptibility testing conditions for dermatophytes. J Clin Microbiol 2002; 40: 3999–4003.
- Grau MT, Romero A, Sacristán A, Ortiz JA. Dermal tolerance and phototoxicity studies of sertaconazole. Arzn Forsch 1992; 42: 746–7.
- Agut J, Tarrida N, Sacristan A, Ortiz JA. Antiinflammatory activity of topically applied sertaconazole nitrate. Meth Find Exp Clin Pharmacol 1996; 18: 233–4.